🦊/Investors

Longwall Venture Partners LLP

Venture capitaloperating company · company profile

Harwell · Seed–Series A · 4 people tracked

Find your way into Longwall Venture Partners LLP

1,066 people in our graph share verified history with the Longwall Venture Partners LLP team — schools, employers, funds. One of them is your warm intro.

Deep Nisharunlockedknows David Denny · together at Harvard Business School (overlapped)
×5knows the team · via Harvard Business School
knows the team · via University of Oxford
×2knows the team · via University of Nottingham
×2knows the team · via PwC
knows the team · via Newcastle University
Fox Verdict
Sign up to see your fit

Investment thesis

Longwall Venture Partners provides early-stage venture capital and company-building support for UK deeptech, helping turn scientific research into enduring global businesses. The firm emphasizes patient capital and technical fluency, recognizing that deep, emergent technology requires investors who understand the long journey from prototype to product and from first customer to category leader. Longwall works closely and deliberately with founders from day one, prioritizing customer engagement and avoiding over-engineering. Active since 2008, it positions itself as a long-term partner willing to back ambitious hard-science ideas that other investors underestimate.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series A
Check
$2M
HQ
Harwell, GB
Leads rounds
Leads
Instruments
Equity
Founded
2008
AUM
$88.9M
Tracked investments
15

Team · 4 people

from the firm's website & public directories

Founder mafia

2 people who came through Longwall Venture Partners LLP went on to found or lead other companies.

What they invest in

from 12 of 15 portfolio companies

Deep Tech ×9Biotech ×7Hardware ×5Healthtech ×5Cleantech ×3Medical Devices ×3Climate Tech ×2Digital Health ×2

HQs:United Kingdom×6

Investments · 15 tracked

founders shown can be your intro path
Biofidelity Revolutionising genomic analysisbiofidelity.comin𝕏

Biofidelity develops decentralized biomarker testing solutions, starting with Aspyre Lung Reagents for analyzing DNA and RNA variants in lung cancer research.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Barnaby Balmforth, PhDJonathan Senior, MD

Co-investorsOctopus VenturesPerscitus LLP

Kinomicakinomica.com

Kinomica develops mass spectrometry-based diagnostic tests that measure protein activity to predict patient responses to multiple drugs.

AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesMacclesfield, GB

Lettusgrowlettusgrow.comin

LettUs Grow develops aeroponic irrigation systems and technologies for controlled environment agriculture, enabling growers to produce fresh food with reduced waste and carbon footprint.

AgTechCleantechClimate TechFoodTechHardwareBristol, GB

Co-investorsBlue Horizon Corporation

Lightcastlightcast.bioin

Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.

BiotechDeep TechHealthtech

Co-investors+ND CapitalIllumina VenturesM VenturesOMX VenturesARCH Venture Partners

MFXmfx.bioin𝕏

MFX develops the Cyto Engine, an automated bioprocessing platform that accelerates development and manufacturing of engineered cells for cell and gene therapy.

BiotechDeep TechHealthtech

Co-investorsCambridge Angels group

MIRICOmirico.co.ukinJul 2022

Mirico provides an automated digital platform for continuous methane emissions measurement and monitoring at industrial sites, delivering real-time data for regulatory reporting and operational optimization.

CleantechClimate TechDeep TechEnergyHardwareIoT

Damien Weidmann(Chief Scientific Officer)

Co-investorsFuture Planet CapitalOxford Investment Opportunity Network (OION)Foresight GroupNew Climate Ventures

OrganOxorganox.comin

OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.

BiotechHealthtechMedical DevicesOxford, GB

Prof. Peter Friend(Co-Founder)

Co-investorsAmadeus Capital PartnersBusiness Growth FundHealthQuest CapitalIntuitive VenturesLauxera Capital PartnersOxford University Innovation+1 more

Oxford Space Systems - companyoxford.space

Oxford Space Systems designs and manufactures deployable antennas for satellites, focused on reducing mass and improving stowage efficiency and performance.

Deep TechHardwareSpace TechHarwell, GB

Sean Sutcliffein

Co-investorsCambridge Angels groupEMV CapitalFuture Planet CapitalMartlet CapitalOxford Investment Opportunity NetworkOxford Investment Opportunity Network (OION)+4 more

Oxfordpvoxfordpv.com

Oxford PV develops perovskite-on-silicon tandem solar cell technology aimed at increasing the efficiency of photovoltaic modules.

CleantechEnergyNew Materials

Co-investorsPerivoli Innovations

Oxsonicsoxsonics.com

OxSonics is a clinical-stage therapeutics company developing a platform technology intended to improve the delivery and penetration of anti-cancer drugs into solid tumours.

BiotechDeep TechHealthtech

Co-investorsPerivoli Innovations

Verdelinstrumentsverdelinstruments.comin

Verdel Instruments develops total correlation mass spectrometry (TOC-MS), a method using stored waveform ion radius modulation (SWIM) to generate MS/MS data for every analyte in a complex mixture.

BiotechDeep TechHardware

Waylandadditivewaylandadditive.comin

Wayland Additive develops electron beam additive manufacturing technology for metal production, leveraging decades of expertise from the semiconductor industry.

Advanced ManufacturingDeep TechHardwareNew Materials

Will Richardsonin

Co-investorsInnovate UK

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Focus SensorsOxfordbio

Portfolio news

latest coverage across their companies

Principals & officers · per Companies House

what is this? ⓘ
Jane Elizabeth Burgoyne

LLP designated member · since 2017

David James Edmonds Denny

LLP designated member · since 2011

Matthew Gerard Winston Frohn

LLP designated member · since 2011

Ownership & control

David James Edmonds Denny25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Matthew Gerard Winston Frohn25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Jane Elizabeth Burgoyne25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Frequently asked questions

How many investments has Longwall Venture Partners LLP made?
Longwall Venture Partners LLP has 15 tracked investments.
What stage does Longwall Venture Partners LLP invest at?
Longwall Venture Partners LLP invests at the Seed, Series A stages.
What is Longwall Venture Partners LLP's typical check size?
Longwall Venture Partners LLP typically writes checks of $2M.
What sectors does Longwall Venture Partners LLP focus on?
Longwall Venture Partners LLP focuses on Biotech, Deep Tech, Hardware, Healthtech, IoT, Medical Devices, New Materials, SaaS.
Where is Longwall Venture Partners LLP located?
Longwall Venture Partners LLP is headquartered in Harwell, GB.
Does Longwall Venture Partners LLP lead rounds?
Yes, Longwall Venture Partners LLP leads investment rounds.
Who does Longwall Venture Partners LLP co-invest with?
Longwall Venture Partners LLP most often shares deals with Perivoli Innovations, Cambridge Angels group, Amadeus Capital Partners, among 25 tracked co-investors.

Similar investors

Featured in lists